Mutual of America Capital Management LLC Takes $784,000 Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Mutual of America Capital Management LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 4,995 shares of the company’s stock, valued at approximately $784,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. International Assets Investment Management LLC purchased a new position in shares of TransMedics Group during the 2nd quarter valued at $47,000. USA Financial Formulas bought a new stake in TransMedics Group during the third quarter valued at $55,000. J.Safra Asset Management Corp grew its position in TransMedics Group by 649.2% during the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after buying an additional 383 shares in the last quarter. Signaturefd LLC increased its stake in TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after acquiring an additional 93 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of TransMedics Group by 187.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after acquiring an additional 316 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $80.61 on Wednesday. The company has a 50-day simple moving average of $116.21 and a two-hundred day simple moving average of $137.14. TransMedics Group, Inc. has a 12-month low of $67.77 and a 12-month high of $177.37. The firm has a market cap of $2.71 billion, a price-to-earnings ratio of 85.76 and a beta of 2.08. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company’s revenue was up 63.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.12) earnings per share. On average, equities analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Analyst Upgrades and Downgrades

TMDX has been the subject of several recent analyst reports. TD Cowen cut their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Canaccord Genuity Group cut their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. JPMorgan Chase & Co. decreased their price target on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a report on Tuesday, October 29th. Oppenheimer dropped their price objective on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Finally, Needham & Company LLC reissued a “hold” rating and issued a $109.00 target price on shares of TransMedics Group in a research note on Friday, November 22nd. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.80.

Insider Activity

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This trade represents a 12.27 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now directly owns 732 shares of the company’s stock, valued at $61,158.60. The trade was a 90.22 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,958 shares of company stock valued at $3,470,328. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.